{"doi":"10.1093/noajnl/vdaa050","title":"Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab","abstract":"Abstract Background Treatment of recurrent glioblastoma (GBM) with bevacizumab can induce MRI changes that confound the determination of progression. We sought to determine the value of [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in GBM patients receiving bevacizumab at the time of suspected progression and, thereby, its utility as a potential prognostic adjunct in progressive disease. Methods This retrospective study included patients who underwent brain FDG PET within 4 weeks of receiving bevacizumab for recurrent GBM with suspected progression. Volumes-of-interest were placed over the reference lesion with measurement of maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), metabolic tumor volume, total lesion glycolysis (TLG), and tumor-to-normal contralateral white matter ratios (TNR-WM). Tumors were additionally categorized as non-avid or avid based on qualitative FDG uptake. Associations between baseline variables and overall survival (OS) were examined using univariable and multivariable Cox proportional hazards regression, with P < .05 considered significant. Results Thirty-one patients were analyzed. Qualitative FDG uptake was significantly associated with OS (P = .03), with a median OS of 9.0 months in non-avid patients versus 4.5 months in avid patients. SUVmax, SUVpeak, TNR-WM, and TLG were significantly associated with OS (P < .001, TLG: P = .009). FDG avidity and SUVmax remained significantly associated with OS (P = .046 and .048, respectively) in the multivariable analysis including age, KPS, and MGMT status. Dichotomizing patients using an SUVmax cutoff of 15.3 was associated with OS (adjusted P = .048). Conclusion FDG PET is a promising imaging tool to further stratify prognosis in recurrent GBM patients on antiangiogenic therapy.","journal":"Neuro-Oncology Advances","year":2020,"id":107191,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9537,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":424344,"name":"Simone Krebs","orcid":"0000-0002-9909-4531","position":1,"is_corresponding":false},{"id":236579,"name":"Tejus Bale","orcid":"0000-0003-3641-9287","position":2,"is_corresponding":false},{"id":516853,"name":"Kwaku Domfe","orcid":null,"position":3,"is_corresponding":false},{"id":325303,"name":"Stephanie Lobaugh","orcid":"0000-0002-6817-8169","position":4,"is_corresponding":false},{"id":255795,"name":"Zhigang Zhang","orcid":"0000-0001-8666-1026","position":5,"is_corresponding":false},{"id":269961,"name":"Mark Dunphy","orcid":"0000-0002-1886-1832","position":6,"is_corresponding":false},{"id":225605,"name":"Thomas Kaley","orcid":"0000-0002-2540-8518","position":7,"is_corresponding":false},{"id":281410,"name":"Robert J. Young","orcid":"0000-0001-7003-3017","position":8,"is_corresponding":false},{"id":397212,"name":"Maya Srikanth Graham","orcid":"0000-0003-4748-974X","position":0,"is_corresponding":true}],"reference_count":30,"raw_metadata":null,"created_at":"2026-07-18T23:12:34.898963Z","pmid":"32642703","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}